Proprietary formulations of WNT stem cell activators fur surgical application

Ankasa Regenerative Therapeutics is pioneering the development of novel protein-based therapies aimed at enhancing stem cell activation for improved tissue repair and regeneration. Central to their approach is the manipulation of the Wnt signaling pathway, which plays a crucial role in stem cell maintenance and tissue regeneration. Ankasa has achieved a significant milestone by being the first company to produce human Wnt proteins in a manufacturing environment suitable for clinical use. Their lead product, ART352-L, is designed to augment the osteogenic properties of patient-derived stem cells, particularly in spinal fusion surgeries, which address degenerative conditions of the intervertebral discs. The preclinical data suggest that ART352-L can significantly enhance bone formation without the risk of unwanted overgrowth, potentially reducing the need for revision surgeries and associated complications.

The therapeutic potential of ART352-L extends beyond spinal fusion, with applications in various bone reconstructive procedures, including dental and orthopedic implants, fracture repair, and total joint arthroplasty revisions. The company is leveraging its established Good Manufacturing Practice (GMP) capabilities and scientific expertise to expand its pipeline, targeting additional indications such as cervical spine procedures and cartilage and tendon repair. With a robust financial backing, including over $19 million from venture investments and grants from The California Institute of Regenerative Medicine, Ankasa is well-positioned to address significant unmet medical needs in bone healing and regeneration.

United States

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L.  Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Ankasa Regenerative Therapeutics

Company Details